Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Intervention of thymus and activation-regulated chemokine attenuates the development of allergic airway inflammation and hyperresponsiveness in mice.

Authors: Kawasaki, S  Takizawa, H  Yoneyama, H  Nakayama, T  Fujisawa, R  Izumizaki, M  Imai, T  Yoshie, O  Homma, I  Yamamoto, K  Matsushima, K 
Citation: Kawasaki S, etal., J Immunol. 2001 Feb 1;166(3):2055-62.
Pubmed: (View Article at PubMed) PMID:11160256

Thymus- and activation-regulated chemokine (TARC; CCL17) is a lymphocyte-directed CC chemokine that specifically chemoattracts CC chemokine receptor 4-positive (CCR4(+)) Th2 cells. To establish the pathophysiological roles of TARC in vivo, we investigated here whether an mAb against TARC could inhibit the induction of asthmatic reaction in mice elicited by OVA. TARC was constitutively expressed in the lung and was up-regulated in allergic inflammation. The specific Ab against TARC attenuated OVA-induced airway eosinophilia and diminished the degree of airway hyperresponsiveness with a concomitant decrease in Th2 cytokine levels. Our results for the first time indicate that TARC is a pivotal chemokine for the development of Th2-dominated experimental allergen-induced asthma with eosinophilia and AHR. This study also represents the first success in controlling Th2 cytokine production in vivo by targeting a chemokine.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 4145603
Created: 2010-11-10
Species: All species
Last Modified: 2010-11-10
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.